

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 841 396 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

13.05.1998 Bulletin 1998/20

(21) Application number: 97307757.1

(22) Date of filing: 01.10.1997

(51) Int. Cl.: C12N 15/54, C12N 9/12,
C12Q 1/68, C12Q 1/48,
C12N 15/11, C12N 15/85,
A01K 67/027, C07K 16/40,
A61K 38/45, A61K 31/70,
C12N 1/21, C12N 1/19

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

Designated Extension States:

AL LT LV RO SI

(30) Priority: 01.10.1996 US 724543

18.04.1997 US 844419

25.04.1997 US 846017

06.05.1997 US 851843

09.05.1997 US 854050

14.08.1997 US 911312

14.08.1997 US 912951

14.08.1997 US 915503

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicants:

- Geron Corporation
Menlo Park, CA 94025 (US)
- University Technology Corporation
Boulder, CO 80301 (US)

(72) Inventors:

- Cech, Thomas R.
Boulder Colorado 80303 (US)
- Lingner, Joachim
Boulder Colorado 80303 (US)

- Nakamura, Toru
Boulder Colorado 80303 (US)
- Chapman, Karen B.
Sausalito California 94965 (US)
- Morin, Cregg B.
Palo Alto California 94303 (US)
- Harley, Calvin
Palo Alto California 94301 (US)
- Andrews, William H.
Richmond California 94085 (US)

(74) Representative: Bizley, Richard Edward et al
Hepworth, Lawrence, Bryer & Bizley
Merlin House
Falconry Court
Baker's Lane
Epping Essex CM16 5DQ (GB)

Remarks:

The applicant has subsequently filed a sequence
listing and declared, that it includes no new matter.
A request for correction of page 33 in the Accession
number at line 13 and for substitution of page 274
has been filed pursuant to Rule 88 EPC. A decision
on the request will be taken during the proceedings
before the Examining Division (Guidelines for
Examination in the EPO, A-V, 3.).

(54) Human telomerase catalytic subunit

(57) The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the inven-

tion are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

EP 0 841 396 A1